CV 4151

Known as: CV-4151 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1985-1999
012319851999

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1995
1995
Effects of thromboxane A2 (TXA2) synthase inhibitors (CV-4151 and ozagrel) on cerebral thrombosis and cerebral damage were… (More)
Is this relevant?
1995
1995
The antiplatelet and antithrombotic effects of CV-4151 (isbogrel), a potent selective thromboxane A2 (TXA2) synthase inhibitor… (More)
Is this relevant?
1993
1993
The effects of CV-4151 on post-ischemic brain hypoperfusion and thromboxane (Tx)A2 production in a canine model of total global… (More)
Is this relevant?
Highly Cited
1989
Highly Cited
1989
This study was undertaken to compare age-related changes in endothelium-dependent vascular responses in both hypertensive and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1988
1988
The pharmacokinetics and pharmacologic effects of a potent, selective inhibitor of thromboxane synthetase, CV-4151 [(E)-7-phenyl… (More)
  • figure 1
  • table I
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1988
1988
The thromboxane A2/prostaglandin endoperoxide (TXA2/PGH2) receptor antagonist activity of CV-4151, a potent TXA2 synthetase… (More)
Is this relevant?
1986
1986
(E)-7-Phenyl-7-(3-pyridyl)-6-heptenoic acid (CV-4151) inhibited horse platelet microsomal thromboxane (TX) A2 synthetase with an… (More)
Is this relevant?
1986
1986
The protective effect of a novel thromboxane (TX) synthetase inhibitor, (E)-7-phenyl-7-(3-pyridyl)-6-heptenoic acid (CV-4151), on… (More)
Is this relevant?
1986
1986
Ten weeks old male Sprague-Dawley rats were used. One mg/kg of a calfskin type III collagen was injected into a tail vein under… (More)
Is this relevant?
1985
1985
When CV-4151, a specific thromboxane (TX) A2 synthetase inhibitor, was given orally to 4 week old (4w) spontaneously hypertensive… (More)
Is this relevant?